Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 13, 2025

Targeting HDAC and PARP Enhances STING-Dependent Antitumor Immunity in STING-Deficient Tumor.

View Full Paper
Ask AI
Bookmark
Share

Authors

CMChengzhou MaoWFWeiwen FanJLJiaqi Liu

Discussion

Loading...

Member takes

Overview

Bifunctional HDAC and PARP inhibitor enhances antitumor immunity in STING-deficient tumors, suggesting a novel therapeutic approach.

Key Points

  • The dual inhibition of HDAC and PARP restores STING expression, which is essential for antitumor immunity.
  • Treatment with the bifunctional inhibitor promotes DNA accumulation in the cytosol, activating the interferon response.
  • Infiltration and activation of T cells and dendritic cells in the tumor microenvironment are significantly improved.
  • The findings highlight a promising strategy to overcome STING deficiencies in tumors and enhance immune responses.

Cite This Study

Mao et al. (2025) studied this question.

synapsesocial.com/papers/689e03efd61984b91e13d55fhttps://doi.org/10.1002/advs.202507904
View Full Paper
Ask AI
Bookmark
Share